The ongoing evolution and novel advancements in filtration technology are essential for biologics manufacturing, as the complexity and size of therapeutic modalities increase. This evolution has introduced new challenges that require efficient and effective filtration systems to ensure the
Amid significant strategic shifts and infrastructural investments, KBI Biopharma has decided to discontinue mammalian drug substance manufacturing at its Geneva, Switzerland facility. This move comes following a period of substantial upgrades and expansion, signaling a concerted effort to
The biopharma sector is at an inflection point as the United States grapples with concerns about China's influence and potential risks posed by collaborations with Chinese military medical institutions. A legislative measure known as the BIOSECURE Act aims to address these apprehensions,
Single-use systems (SUS) have revolutionized biopharmaceutical manufacturing, with single-use bioreactors (SUBs) leading the charge in recent decades. However, while the adoption of SUBs has plateaued, other forms of single-use technology (SUT) are gaining momentum. The landscape is evolving
The bioprocessing sector, a critical component within the Life Sciences industry, continually faces hurdles in bringing innovative technologies from development to market. BioProcess360 Partners has introduced a novel investment fund aimed at bridging this gap. By providing both capital and
Optimizing cell line development (CLD) for next-generation biologics is crucial to meet the rapidly growing demand for novel therapeutic modalities. As the biologics sector evolves, it's imperative to address potential bottlenecks in the development process through strategic enhancements and
